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ABSTRACT 
BACKGROUND:  Mucopolysaccharidoses (MPSs) are a group of severe metabolic 
disorders caused by deficiencies in enzymes involved in the degradation ofglycosamino- 
glycans (GAGs) long chains of sugar carbohydrates in cells that help build bone, 
cartilage, tendons, corneas, skin, and connective tissue. Although enzyme replacement 
therapy has become available fbr the treatment of some types of MPS, effective treat- 
ment of neurodegenerative forms of MPS has yet to be determined. Recently, genistein 
(4~,5,7-trihydroxyisoflavone), a specific inhibitor of protein tyrosine kinase, has been 
found to inhibit GAG synthesis and to reduce GAG concentrations in cultures of 
fibroblasts of MPS patients. Therefore, a potential substrate reduction therapy has been 
proposed. 
OBJECTIVE: :  The aim of this study was to examine urinary GAG concentration, 
hair morphology, and cognitive function in patients receiving genistin treatment for 
Sanfilippo syndrome (MPS type III). 
19IETHOlaS: Patients aged 3 to 14 years with a biochemically confirmed iagno- 
sis of MPS IIIA or MPS IIIB were eligible to enroll in this open-labd, pilot study. 
Genistin-rich soy isoflavone xtract 5 mg/kg/d was administered PO for 12 months. 
Urinary GAG concentration, hair morphology, and cognitive function (measured using 
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a modified version of the Brief Assessment Examination [BAE] and parent observa- 
tions) were measured at baseline and after 12 months of treatment. 
RESUt.TS: Ten patients (6 girls, 4 boys; mean age, 8 years [range, 3 14 years]; mean 
weight, 28 kg [range, 17 43 kg]) were included in the study. All patients had Sanfilippo 
syndrome; 5 patients had MPS IIIA and 5 had MPS IIIB. After 1 year, statistically sig- 
nificant improvement was found in urinary GAG concentration, hair morphology, and 
cognitive function. Urinary GAG concentration decreased significantly in all 5 patients 
with MPS IIIA and in 2 patients wkh MPS IIIB (P 0.028). Hair morphology improved 
significantly in all 5 MPS IIIA patients and in 3 MPS IIIB patients (P 0.012). A signifi- 
cant increase in the BAE score (by 2 6 points) was noted in 8 patients, wtflle the scores 
of 2 patients did not change after 12 months of treatment (P 0.012). No adverse vents 
(AEs) considered related to treatment were reported. Moreover, no AEs not related to the 
treatment (apart from classical symptoms of MPS III) were noted. 
CONCt.USlONS: This pilot study found some improvements in GAG concentra- 
tion, hair morphology, and cognitive function in these pediatric patients with Sanfilippo 
syndrome treated with genistin-rich soy isoflavone xtract for 1 year. Clinical trials are 
needed to evaluate the efficacy and safety of this potential treatment. (Cur*" Ther Res C/i,v 
E~tg. 2008;69:166 179) (© 2008 Excerpta Medica Inc. 
KEY WORDS: mucopolysaccharidosis, ubstrate reduction therapy, genistdn, genistin, 
gene expression. 
INTRODUCTION 
Mucopolysaccharidoses (MPSs) are genetic diseases that are inherited in an autosomal 
recessive manner (except MPS II, which is X-linked). z Storage of glycosaminoglycans 
(GAGs) in cells of patients with MPS results in progressive damage of the affbcted tis- 
sues, including the heart, respiratory system, bones, joints, and, in some cases, the 
central nervous ystem (CNS)3 In nearly all cases, except for extremely mild ones (which 
are rare), the disease is fatal, with an average xpected life span of 1 to 2 decades. 1 
However, prediction of its severity and clinical progression is usually difficult, even 
when biochemical nd genetic data are available. 2 
Until 2003, no effective, approved treatment was available for all types of MPS. 
Currently, enzyme replacement therapy (ERT), which includes IV infusion of an active, 
recombinant form of a deficient enzyme, can be used for treatment of MPS I, MPS II, 
and MPS VI. 3~ This therapy is effbctive in treatment of somatic symptoms (eg, reduc- 
tion in urinary GAG concentration, decrease in hepatosplenomegaly, improvements in
heart and pulmonary functions, increased joint motion)) ~ However, neurologic symp- 
toms due to GAG accumulation i  the CNS cannot be managed by ERT because of 
inefficient delivery of proteins across the blood-brain barrier. CNS symptoms occur in 
some MPS I patients (subtype MPS IH), in most MPS II and MPS VII patients, and in 
all MPS III patients, in whom they are especially severe. 1Although intrathecal dmin- 
istration of c*-L-iduronidase was found to reduce lysosomal GAG storage in the brain 
and meninges in the canine model of MPS I, s,9 such a therapy might be problematic as 
a chronic treatment in humans because of the risk associated with this invasive proce- 
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dure, which includes the frequency with which it would need to be performed (usually 
weekly) and the need to immobilize the patient. Pediatric patients with MPS are usu- 
ally not compliant with medical procedures, and a W anesthetic procedure is associated 
with high risk in these patients due to problems with intubation. 1 Bone marrow and 
cord blood transplantation were found to some extent o protect against he develop- 
ment of severe CNS symptoms when performed early (up to the second year of life); but 
such treatments did not restore function that had already been lost. 1° 
Sanfilippo syndrome (MPS type III) comprises 4 subtypes (MPS IIIA, B, C, and D) 
that have similar clinical symptoms and are characterized by lysosomal storage of the 
GAG heparan sulfate (ITS). 1 This condition is associated with severe learning disabili- 
ties, behavioral disturbances, and relatively mild somatic involvement. In all affected 
patients (except very rare cases of extremely mild symptoms), the progressive nature of 
the disease leads to death in the second (or rarely the third) decade of life. 1 Because this 
disorder primarily affects the brain and nervous ystem, attempts to cure patients have 
not been successful, with treatment being limited to palliative or symptomatic care. 1
Our previous tudy n found that the isoflavone genistein (4",5,7-trihydroxyisoflavone 
or 5,7-ditlydroxy-3-[4-hydroxyphenyl]-4H-l-benzopyran-4-one) inhibited GAG synthesis 
in fibroblasts of MPS I, MPS II, MPS IIIA, and MPS IIIB patients, as measured by 
incorporating a radioactive precursor. This inhibition led to a decrease in lysosomal 
GAG storage that was observed after 1 week of incubation of fibroblasts with genistein 
at concentrations between 10 and 30 laM (determ ined biochemically by measuring intra- 
cellular GAG concentration a d in electron microscopic studies by observation and count- 
ing atypical intracellular structures). 
The rationale for the use of genistein was based on previous observations that maxi- 
mum synthesis of some GAGs requires either fbllicle-stimulating hormone or epidermal 
growth factor (EGF). 12,13 EGF influences expression of certain genes by binding to its 
transmembrane r ceptor, wtdch then becomes an active protein kinase, initiating a 
specific kinase cascade that finally results in regulation of activity of particular tran- 
scription factors. This tyrosine-specific protein kinase activity of the EGF receptor is 
inhibited by genistein. 14,15 Therefore, we proposed to use a potential substrate reduction 
therapy that is based on the action of genistein. 
In a landmark study, 16 genistein was fbund to cross the blood-brain barrier in rats. 
A subsequent study 17 found that another inhibitor of GAG synthesis, rhodamine B, 
appeared to be effective in the treatment of MPS IIIA in mice. After administration of
rhodamine B 1 mg/kg, reduction of GAG storage was evident in the brain, although a
decrease in urinary GAG concentration was less pronounced compared with untreated 
mice. iv The mechanism of action of rhodamine B is unknown, and the use of this com- 
pound in clinical practice is unlikely due to possible toxic effects, iv However, a similar 
degree of inhibition of GAG synthesis in fibroblasts was achieved using genistein 
and rhodamine B. ll'17 Genistein has been reported to have good [olerability and a 
good safety profile, is 20 Therefore, we decided to perform a pilot clinical study with 
Sanfilippo patients in which urinary GAG concentration, hair morphology, and cogni- 
tive function were examined using previously developed and verified methods 21 26 that 
were validated in our laboratories. 
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PAT IENTS AND METHODS 
PAT IENTS 
Patients with a biochemically confirmed iagnosis and aged between 3 and 14 years 
were eligible to enroll in this open-label, pilot study. 
Sanfilippo syndrome (MPS IIIA or MPS IIIB) was diagnosed by estimating urinary 
GAG concentration (considerably elevated [defined as >1 SD]), using semiquantitative 
turbimetric analysis, and the identification of GAG excretion pattern (ie, presence of 
HS) as primary indicators for MPS, and measuring the activities of particular lysosomal 
hydrolases in leukocytes. Deficiency in activity of heparan N-sulfatase (mean [SDt 
control value: 4.1 [1.4t nmol/mg protein for 18 hours) and c~-N-acetylglucosaminidase 
(mean [SDt control value Ira1:90 [341 nmol/mg protein for 42 hours) were considered 
diagnostic riteria for MPS IIIA and MPS IIIB, respectively. This diagnostic procedure 
was validated in our laboratory. 
P ILOT CL IN ICAL  STUDY 
Patients with MPS IIIA and MPS IIIB were eligible fbr this open-label, pilot clinical 
study in which a genistin-rich soy isoflavone xtract was administered orally for 12 months. 
The extract, SE-2000, was provided by Biofarm International, Ltd., Poznan, Poland. 
SE-2000 consists of genistin and genistein (26.90%), daidzin and daidzein (13.37%), 
glicitin and glycitein (1.98%), soy proteins, carbohydrates, and lipids (remaining 
amount). Genistin is a glycan that can be converted to genistein by either an acid envi- 
ronment or intestinal bacteria. The extract was administered orally at a dose corre- 
sponding to 5 mg of genistin and genistein kg/d. 
Three parameters urinary GAG concentration, hair morphology, and cognitive 
function were estimated at baseline and after 12 months of the treatment. Since 
patients received the extract at home and visited the clinic for study purposes only at 
baseline and after 12 months of treatment, he monitoring of adverse vents (AEs) was 
based on reports of the parents, who were instructed to report AEs immediately (by 
telephone or e-mail, with confirmation of receipt of the information). Parents also pro- 
vided a written assessment of the AEs every 3 months, even if no AEs were observed. 
This pilot clinical study was approved by the Independent Bioethics Committee of 
the Medical University of Gdansk, Gdansk, Poland. The parents of the children 
involved in the study provided written informed consent. 
Estimation off Urinary Heparan Sulfate Concenh~tion 
In all MPS types, elevated urinary GAG concentration is a characteristic feature, 
which is employed in both diagnostics and monitoring of treatment. 3~ Because HS 
is the only GAG that accumulates in MPS III, we measured this compound in urine 
samples of the patients using a method that was previously reported to be adequate and 
able to produce results compatible with other commonly used methods. 25'26 The uri- 
nary HS concentrations were determined using an HS enzyme-linked immunoassay kit 
(Seikagaku Corporation, ~lbkyo, Japan) according to the manufacturer's instruction and 
were calculated as milligrams of HS per grain of creatinine. Creatinine concentration was 
determined using a QuantiChrom TM creatinine assay kit (DICT-500, BioAssay Systems, 
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Hayward, California) for quantitative cobrimetric reatinine determination at 510 nm. 
Urine collections were analyzed at 24-hour intervals. 
Hair Morphology Evaluation 
Hair morphology is considerably changed in patients with MPS I, MPS II, MPS 
IliA, and MPS IIIB and can be visualized using electron microscopic analyses. 21 
Moreover, hair morphology has been found to normalize within 12 months of starting 
ERT in MPS I patients, 24 indicating that it could be used to assess the effectiveness of
treatment. 
The evaluation we used was based on a previously published method that used a 
semiquantitative scale (0 normal hair morphology; 1 minor changes in hair surface 
fie, minor cavity-]; 2 deeper cavity and hilly hair surface; 3 unambiguous concave 
and convex areas on the long hair axis with appearance of the hair as flat in some 
area; 4 deeper changes of the type characteristic for score 3; and 5 the most severe 
hair morphology abnormalities, which include, apart from features described above, 
characteristic hair twisting) assessing hair morphology in MPS. 21 It has been found 
to be appropriate for use in clinical studies. During the procedure, a hair sample (each 
including a hair follicle) was collected from the scalp of each patient. The samples were 
sterilized prior to examination in the scanning electron microscope by washing with 
5% sodium dodecyl sulfate for 20 minutes and then rinsing twice in distilled water for 
15 minutes. Air-dried hair samples were attached to an SPI carbon conductive double- 
sided adhesive disc. The samples were gold-coated (SPI Module 'rM Sputter Coater; SPI 
Supplies, SX/est Chester, PennsyNania) for 120 seconds. Scanning electron micrographs 
were obtained using a Philips XL30 microscope (FEI Worldwide Corporate, Hillsboro, 
Oregon) operating at 5 kV-acceleration. 
Brief Assessme,,t Examination 
Since severe learning disabilities, behavioral disturbances, and neurologic symptoms 
are the most pronounced problems in Sanfilippo syndrome, assessment of cognitive 
function in the patients was crucial to estimate the effects of therapy. A modified 
version of the Brief Assessment Examination (BAE) 22'23 was used to assess cognitive 
and behavioral changes at baseline and after 1 year of treatment. This test has been 
validated for children with severe mental disorders. The following 8 parameters were 
estimated: alertness/activity; obeying commands; pointing at objects; pointing at colors; 
matching shapes; speech; auditory digit span; and mathematics ( core maximum for 
each parameter was 6 or 7, depending on the individual measuremen0. The overall BAE 
scale ranged from 0 to 52 (0 no contact with the tested child and 52 normal score 
for properly developed child at the age of 3 years). 
Parents' Obse,wations 
The parents of the patients were given a questionnaire on which they were asked to 
assess 18 parameters egarding changes in the condition of their children from 1 year 
before treatment to the start of treatment and from the start of treatment to the end of 
treatment. The parents performed the first assessment prior to the start of treatment 
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and performed the latter assessment a the end of the study (ie, after 12 months). They 
were instructed to be objective. Some parents reported they relied, in part, on the 
opinion of other, uninitiated persons (eg, teachers). Nevertheless, it is worth noting that 
responses could be subject o recall bias and the results might have been subjective. 
STATISTICAL ANALYSIS 
Data were analyzed using Statistica software version 7 (StatSoft, Inc., ~l~lsa, Okla- 
homa). The "@~ilcoxon signed rank test 27 was used for comparison between baseline and 
after a year of treatment. A P < 0.05 value was considered statistically significant. 
RESULTS 
Ten patients (6 girls, 4 boys; mean age, 8 years [range, 3 14 yearsJ; mean weight, 28 kg 
[range, 17 43 kg]) were included in the study (Table I). All patients were clinically 
diagnosed with Sanfilippo syndrome according to diagnostic riteria. Of the patients 
included in the stud},, 5patients had MPS IliA and 5 had MPS IIIB. All patients received 
a genistin-rich soy isoflavone xtract (genistein and genistein content 5 mg/kg/d) 
administered PO for 12 months. 
A significant decrease (P 0.028) in urinary HS excretion was observed in all MPS 
IliA patients and 2 MPS IIIB patients treated with the extract (Figure 1). 
Hair morphology improved significantly (P 0.012) in all 5 MPS IliA patients and 
in 3 MPS IIIB patients after 12 months of treatment (Table II). Figure 2 illustrates 
this improvement in 1 MPS IliA patient. In the 2 MPS IIIB patients (IIIB-1 and 
IIIB-2) in whom no changes were noted, the initial abnormality of hair morphology 
was very mild (score 1). 
Table I. Baseline demographic and clinical characteristics of the study patients (N = 10). 
Residual 
Enzyme 
MPS Type Patient No. Sex Age, y Weight, kg Activity* 
IlIA IliA-1 Male 6 25 0.3 
IliA-2 Female 5 18 0 .01 
ILIA-3 Male 3 17 0.3 
IliA-4 Female 6 28 0.12 
ILIA-5 Male 7 30  1.5 
IIIB IIIB-1 Female 11 29 0.1 
IIIB-2 Male 14 36  3.0 
IIIB-3 Female 6 24 8.5  
IIIB-4 Female 13 31 2.6 
IIIB-5 Female 9 43 0 .01 
MPS = mucopolysaccharidosis. 
*Residual activities of enzymes deficient in MPS IlIA and MPS IIIB were measured in leukocytes, and 
were determined as heparan N-sulfatase (MPS IliA) in nmol/mg of protein • 18 h (controls, 4.1 [1.4]) 
or as c~-N-acetylghcosaminidase (MPS IIIB) in nmol/mg of protein • 42 h (controls, 90 [34]). 
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Figure 1. Urinary heparan sulfate (HS) concentrations in patients with mucopolysacchari- 
dosis (MPS) i l ia or l l iB treated with a genistin-rich isoflavone extract.  (Median 
values are shown by the dashed horizontal bars at baseline and 12 months.) 
P = 0 .028  versus baseline. Signif icant changes were found in patients I l iA - l ,  
I l iA-2, I l iA-3, i l iA-4, I l iA-5, I I IB-3, and I l IB-5. 
A significant increase in the BAE score (by 2 6 points) was noted in 8 patients, 
while the scores of 2 patients did not change after 12 months of treatment (P 0.012) 
(Table II). 
Of the 18 variables assessed in the questionnaire garding changes in the condition 
of their children, the parents reported eterioration i many parameters in the period 
from 1 year before treatment to the start of the study, while they described improve- 
ment in these paramemrs f~:om baseline to after 12 months of treatment. After 12 months 
of treatment, he parents reported subjective improvements in hair structure (assessed 
by touching), stool tJ:equency and consistency, and the frequency and severity of infections 
in 8 patients; improvement in sleep habits in 7 patients; improvements in speech corn- 
prehension, general behavior, and skin elasticity (assessed by touching) in 6 patients; and 
improvements in speech performance and dyspeptic symptoms in 3 patients (Table III). 
No AEs considered to be related to the isoflavone xtract were noted during the 
study period. Moreover, no AEs that were not related to the treatment (apart from clas= 
sica.l symptoms of MPS III) were reported. 
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Table II. Hair morphology assessed using electron microscopy and cognit ive funct ion 
assessed using the Brief Assessment Examinat ion (BAE) at basel ine and after 
12 months of t reatment  wi th  genist in-r ich isoflavone extract .  2z-23 
Hair Morphology Score* BAE Scorer 
Patient No. Baseline 12 Months Baseline 12 Months 
ILIA-1 1 0¢ 19 23¢ 
ILIA-2 1 0¢ 14 19¢ 
ILIA-3 2 1¢ 36 36 
ILIA-4 2 1¢ 0 4¢ 
ILIA-5 3 1¢ 11 17¢ 
IIIB-1 1 1 9 12¢ 
IIIB-2 1 1 33 36¢ 
IIIB-3 2 1¢ 12 12 
IIIB-4 3 2¢ 4 6¢ 
IIIB-5 3 1¢ 27 32¢ 
*Scale: 0 = normal to 5 = most abnormal. 
t Scale: 0 = no contact with the tested child to 52 
age of 3 years. 
CP = 0.012 versus baseline. 
= normal score for properly developed child at the 
Baseline 12 Months Control 
200x 
800x 
Figure 2. An example of hair morphology in a healthy child and a pat ient  wi th  
mucopolysacchar idosis  i l iA at baseline and after 12 months of t reatment  wi th  
a genist in-r ich isoflavone extract  (electron microscopy, original magnif icat ion 
200X and 800X).  Morphology scale: 0 = normal hair morphology; I = minor 
changes in hair surface (ie, minor cavity); 2 = deeper cavi ty  and hilly hair 
surface; 3 = unambiguous concave and convex areas on the long hair axis with 
appearance of the hair as f iat  in some area; 4 = deeper changes of the type 
characteristic for score 3; 5 = the most severe hair morphology abnormal i t ies  
which include, apart from features described above, characteristic hair twist ing. 
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DISCUSSION 
In this report we described results of an open-label, pilot clinical study in 10 patients 
with 2 types of Sanfilippo syndrome (MPS IliA or MPS IIIB). The aim of this study 
was to perfbrm a preliminary assessment of the effects of treatment with a genistin-rich 
soy isoflavone xtract. This was based on results of our previous study ll in which we 
found that genistein inhibited synthesis of GAGs in cultured fibroblasts, and that pro- 
longed incubation of cells of MPS patients with genistein resulted in a decrease in stor- 
age material. 
Patients were treated for 12 months with genistin-rich isoflavone xtract 5 (genistin 
and genistein content 5 mg/kg/d) and 3 main variables were measure~ur inary  
GAG concentration, hair morpholog> and cognitive function. In all cases, statistically 
significant improvements were found between values measured at baseline and after 
12 months of treatment. 
Urinary GAG concentration decreased significantly in 7 patients after 12 months of 
the treatment compared with baseline. The absence of a decrease in HS concentration i  
3 patients might be due to high dw-to-d W variability in urinary GAG concentration, 
as reported by others. 25 Residual enzyme activity was different among all 10 patients, 
with no correlation between this parameter and HS levels. Therefore, this variable could 
not be crucial in the changes in urinary HS excretion. The 3 patients whose urinary HS 
excretion did not change were the oldest patients in this study (ages 11, 13, and 14). It is 
possible that a longer time might be required to observe significant changes in urinary 
GAG concentration i  older patients. 
Hair morphology improved significantly in 8 patients after 12 months of treatment. 
This finding, although of little importance for patients' quality of life, was a good pre- 
liminary indicator of the effectiveness of the MPS therapy. 21,24,2~ The dysmorphology 
of hair strands of MPS I patients was found to improve during ERT24,2~; the changes 
in hair morphology characteristic of MPS I also were found in MPS II, MPS IliA, and 
MPS IIIB. el Therefore, improvement in hair morphology in the MPS III patients in 
our study might reflect generally positive effects of treatment with this genistin-rich 
isoflavone xtract. 
Since severe learning disabilities, behavioral disturbances, and neurologic symptoms 
occur in Sanfilippo syndrome, we assessed cognitive function of all patients at baseline 
and af}er 12 months of treatment. We used a modified version of the BAE that allowed 
measurement of cognitive and behavioral functions in severely disabled children. 22,23 
Significant improvement was found in 8 patients, while there was no change in the 
BAE score in the other 2 patients. Gradual mental deterioration occurs in Sanfilippo 
patients after they are aged 3 to 5 years. 1The condition of each patient in this study 
was deteriorating when treatment was started. "Worsening mental status was not found 
in any of the study patients afier 1 year of treatment compared with baseline. These 
findings might suggest hat treatment had positive effects on mental and cognitive 
functions in these patients with MPS IIIA and MPS IIIB. However, temporal changes 
in children cannot be excluded, since there was no control group and the study de- 
sign was not blind. This might be considered as a limitation in interpretation f our re- 
suits. Some parents reported subjective improvements in speech performance (5 patients), 
175 
CURRENT THERAPEUTIC  RESEARCH 
speech comprehension (6 patients), activity (4 patients), and general behavior (6 patients) 
after 12 months of treatment compared with baseline, while all parents reported ete- 
rioration or no change in these variables from 1 year before treatment to the start of 
treatment. This seems to be compatible with the remainder of our findings and sup- 
ports the preliminary positive results of this therapy. 
The potential subjectivity of the parents' opinions in the 18 variables regarding their 
children's condition before and after treatment must be considered, although the parents 
were instructed to be objective. There were some indications that the parents attempted 
to complete the questionnaire in an objective manner. First, as there are generally no 
serious problems with vision or breathing in patients with MPS III, these questions 
were designed to be control questions. In fact, most parents indicated there were no 
changes in these variables in either period. If the opinions were subjective, the parents 
might have reported improvement in these variables. Second, patients IIIA-1 and IIIA-3 
were siblings, as were patients IIIB-1 and IIIB-4. Although both pairs of siblings were 
assessed by the same pairs of parents, the answers provided in the questionnaire dif~ 
fered considerably from one sibling to the other, which would not be expected in the 
case of subjective opinions. Furthermore, some parents reported they depended on the 
opinion of other, uninvolved persons (eg, teachers). This might have decreased the level 
of subjectivity in the assessment ofparticular variables. 
Sanfilippo syndrome is a lysosomal storage disease (LSD) that is difficult to treat 
because the neurologic symptoms associated with the disease cannot be effectively 
managed using ERT, which is associated with inefficient delivery of the enzymes 
across the blood-brain barrier. Recent clinical studies 2s 30 of substrate reduction 
therapy in Niemann-Pick type C disease found some improvement, particularly in 
horizontal saccadic eye movement velocity, swallowing capacity, and stable auditory 
acuity, in patients with this neurodegenerative LSD. Positive effects of substrate 
reduction therapy on cognitive and behavioral functions might also be suggested on 
the basis of results presented in this preliminary report. To our knowledge, this is the 
first report that found positive effbcts in patients with MPS III following 1 year of 
pharmacologic treatment. Clinical trials are needed to evaluate the efficacy and safety 
of this potential treatment. 
CONCLUSIONS 
This open-label pilot study fbund some improvements in GAG concentration, hair 
morphology, and cognitive function in these pediatric patients with Sanfilippo syn- 
drome treated with genistin-rich soy isoflavone xtract for 1 year. 
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